{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(16)"],"submitter":["Dangas G"],"pubmed_abstract":["<h4>Background</h4>In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).<h4>Aims</h4>The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type.<h4>Methods</h4>In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation.<h4>Results</h4>"],"journal":["EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology"],"pagination":["1330-1339"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9743248"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study."],"pmcid":["PMC9743248"],"pubmed_authors":["Steg PG","Witzenbichler B","Gil R","Kunadian V","Cao D","Oldroyd KG","Pocock S","Kaul U","Camaj A","Giustino G","Moliterno DJ","Huber K","Collier T","Goel R","Sardella G","Mehta S","Briguori C","Weisz G","Gibson CM","Kastrati A","Mehran R","Dudek D","Sharma S","Sartori S","Kornowski R","Nicolas J","Ohman EM","Escaned J","Baber U","Angiolillo DJ","Dangas G","Zhang Z","Shlofmitz R","Krucoff MW","Han YL","Cohen D"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.","description":"<h4>Background</h4>In the TWILIGHT trial, ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) was shown to be a safe bleeding avoidance strategy in high-risk patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).<h4>Aims</h4>The aim of this study was to evaluate the effects of ticagrelor monotherapy after three-month DAPT in patients undergoing PCI, according to DES type.<h4>Methods</h4>In the current sub-analysis from TWILIGHT, patients were stratified into three groups based on DES type: durable polymer everolimus-eluting stents (DP-EES), durable polymer zotarolimus-eluting stents (DP-ZES), and biodegradable polymer DES (BP-DES). Bleeding and ischaemic outcomes were assessed at one year after randomisation.<h4>Results</h4>","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T12:29:06.759Z","creation":"2025-04-04T12:29:06.759Z"},"accession":"S-EPMC9743248","cross_references":{"pubmed":["34881696"],"doi":["10.4244/eij-d-21-00721","10.4244/EIJ-D-21-00721"]}}